Furthermore, previous studies indicated AHNKA2 as a possible new therapeutic target in some cancers because it would play an important role in regulating multiple tumor progression pathways, including mitogen-activated protein kinase (MAPK)/extracellular signal-regulated kinase (ERK), phosphatidylinositol 3-kinase (PI3K)/protein kinase B (AKT), hypoxia inducible factor-1α (HIF-1α), and transforming growth factor-β (TGF-β)/Smad3 [10,12,15,16]. Here, AKT1 is linked to cancer.